reported that an autophagy inhibitor in combination with dual ICIs, anti‐CTLA4 Ab plus anti‐PD1 Ab, protected against pancreatic cancer growth in a murine isograft model.23 This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.